About: Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study
Creator	Li, Man Wang, David Hu, Bo Chang, Jiang Jin, Huijuan Li, Yanan Mao, Ling Wang, Mengdie Zhou, Yifan Xian, Ying
Source	Medline; PMC
abstract	BACKGROUND AND PURPOSE: COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Apart from respiratory complications, acute cerebrovascular disease (CVD) has been observed in some patients with COVID-19. Therefore, we described the clinical characteristics, laboratory features, treatment and outcomes of CVD complicating SARS-CoV-2 infection. MATERIALS AND METHODS: Demographic and clinical characteristics, laboratory findings, treatments and clinical outcomes were collected and analysed. Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared. RESULTS: Of 219 patients with COVID-19, 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. COVID-19 with new onset of CVD were significantly older (75.7±10.8 years vs 52.1±15.3 years, p<0.001), more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01) and were more likely to have cardiovascular risk factors, including hypertension, diabetes and medical history of CVD (all p<0.05). In addition, they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein (51.1 (1.3–127.9) vs 12.1 (0.1–212.0) mg/L, p<0.05) and D-dimer (6.9 (0.3–20.0) vs 0.5 (0.1–20.0) mg/L, p<0.001). Of 10 patients with ischemic stroke; 6 received antiplatelet treatment with aspirin or clopidogrel; and 3 of them died. The other four patients received anticoagulant treatment with enoxaparin and 2 of them died. As of 24 March 2020, six patients with CVD died (54.5%). CONCLUSION: Acute CVD is not uncommon in COVID-19. Our findings suggest that older patients with risk factors are more likely to develop CVD. The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.
has issue date	2020-07-02(xsd:dateTime)
bibo:doi	10.1136/svn-2020-000431
bibo:pmid	32616524
has license	cc-by-nc
sha1sum (hex)	416590e249a72137a2bbaa0936e128e6e83d3890
schema:url	https://doi.org/10.1136/svn-2020-000431
resource representing a document's title	Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study
has PubMed Central identifier	PMC7371480
has PubMed identifier	32616524
schema:publication	Stroke Vasc Neurol
resource representing a document's body	covid:416590e249a72137a2bbaa0936e128e6e83d3890#body_text
is schema:about of	named entity 'Acute' named entity 'case series' named entity 'intracerebral haemorrhage' named entity 'severe pneumonia' named entity 'consciousness' named entity 'COVID' named entity 'COVID' named entity 'lab tests' named entity 'COVID' named entity 'T2-weighted' named entity 'elevated blood glucose' named entity 'risk factors' named entity 'intracerebral haemorrhage' named entity 'interruption of the blood supply' named entity 'high levels' named entity 'electronic medical records' named entity 'SARS-CoV-2' named entity 'subcortical' named entity 'Wilcoxon rank-sum test' named entity 'COVID' named entity 'atrial fibrillation' named entity 'intracerebral haemorrhage' named entity 'COVID' named entity 'clinical characteristics' named entity 'WHO' named entity 'asymptomatic infection' named entity 'brain MRI' named entity 'COVID' named entity 'infection' named entity 'antiplatelet' named entity 'neuronal damage' named entity 'SARS-CoV-2' named entity 'case report' named entity 'hypercoagulable state' named entity '28 days' named entity 'acute inflammation' named entity 'coagulation abnormalities' named entity 'proinflammatory cytokines' named entity 'Open access' named entity 'statistically significant' named entity 'National Institute of Health' named entity 'COVID' named entity 'ischaemic stroke' named entity 'neurological symptoms' named entity 'D-dimer' named entity 'inflammatory factors' named entity 'asymptomatic' named entity 'ischaemic stroke' named entity 'Huazhong University of Science and Technology' named entity 'mm Hg' named entity 'neurological symptoms' named entity 'corona virus' named entity 'enoxaparin' named entity 'blood coagulation' named entity 'infection' named entity 'infection' named entity 'COVID' named entity 'antiplatelet' named entity 'inflammatory' named entity 'increased blood pressure' named entity 'inflammatory response' named entity 'PCR' named entity 'PCR' named entity 'infection' named entity 'SARS-CoV' named entity 'CVDs' named entity 'stroke' named entity 'clinical symptoms' named entity 'China' named entity 'COVID' named entity '2.04' named entity 'risk factors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software